TABLE 1.
Clinical characteristics of each of the two groups in the allo-HSCT cohorta
| Characteristic | Result for the following cases: |
P value | ||
|---|---|---|---|---|
| Total (n = 768) | Cases with BC (n = 26) | Cases without BC (n = 742) | ||
| Median (range) age (yr) | 55 (16–74) | 53 (22–69) | 55 (16–74) | 0.41 |
| No. (%) male patients/no. (%) female patients | 488/280 | 18 (69)/8 (31) | 470 (63)/272 (37) | 0.68 |
| No. (%) of patients with the following diagnosis: | ||||
| AML | 406 | 15 (58) | 391 (53) | 0.69 |
| MDS | 64 | 1 (3.8) | 63 (8.5) | 0.72 |
| CML | 24 | 1 (3.8) | 23 (31) | 0.57 |
| ALL | 101 | 4 (15) | 97 (13) | 0.77 |
| HL | 14 | 0 | 14 (19) | 1 |
| NHL | 84 | 3 (12) | 81 (11) | 0.76 |
| ATLL | 18 | 0 | 18 (2.4) | 1 |
| SAA | 15 | 1 (3.8) | 14 (1.9) | 0.41 |
| MM | 5 | 0 | 5 (0.7) | 1 |
| Others | 37 | 1 (3.8) | 36 (4.9) | 1 |
| No. (%) of patients with underlying diabetes mellitus | 68 | 2 (7.7) | 66 (8.9) | 1 |
| No. (%) of patients with the following disease risk: | ||||
| Standard risk | 101 | 2 (7.7) | 99 (13) | 0.56 |
| High risk | 667 | 24 (92) | 643 (87) | |
| No. (%) of patients with the following conditioning: | ||||
| RIC | 258 | 9 (35) | 249 (34) | 1 |
| MAC | 510 | 17 (65) | 493 (66) | |
| No. (%) of patients treated with the following agent(s) for GVHD prophylaxis: | ||||
| TAC | 187 | 9 (35) | 178 (24) | 0.24 |
| TAC + MMF | 385 | 14 (54) | 371 (50) | 0.84 |
| TAC + sMTX | 125 | 1 (3.8) | 124 (17) | 0.1 |
| CsA + sMTX | 56 | 2 (7.7) | 54 (7.3) | 0.71 |
| Others | 15 | 0 | 15 (2) | 1 |
| No. (%) of patients with the following transplant type: | ||||
| CBT | 549 | 21 (81) | 528 (71) | 0.38 |
| rPBSCT | 76 | 1 (3.8) | 75 (10) | 0.5 |
| uBMT | 143 | 4 (15) | 139 (19) | 0.8 |
| No. (%) of patients with the following HLA disparity: | ||||
| Matched | 178 | 4 (15) | 174 (23) | 0.48 |
| Mismatched | 590 | 22 (85) | 568 (77) | |
| No. (%) of patients with pretransplant status of LSNP until day 0 of ≥5 days | 276 | 15 (58) | 261 (35) | 0.023 |
| No. (%) of patients treated with the following antifungal agent at day 0: | ||||
| MCFG | 444 | 16 (62) | 428 (52) | 0.84 |
| VRC | 164 | 4 (15) | 160 (22) | 0.63 |
| ITC | 82 | 3 (12) | 79 (11) | 0.75 |
| LAMB | 73 | 3 (12) | 70 (9.4) | 0.73 |
| Others | 5 | 0 | 5 (0.7) | 1 |
allo-HSCT, allogeneic hematopoietic stem cell transplantation; BC, breakthrough candidemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; ALL, acute lymphoblastic leukemia; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; ATLL, adult T cell leukemia/lymphoma; SAA, severe aplastic anemia; MM, multiple myeloma; RIC, reduced-intensity conditioning; MAC, myeloablative conditioning; GVHD, graft-versus-host disease; TAC, tacrolimus; MMF, mycophenolate mofetil; sMTX, short-term methotrexate; CsA, cyclosporine; CBT, cord blood transplantation; rPBSCT, related peripheral blood stem cell transplantation; uBMT, unrelated bone marrow transplantation; LSNP, longer severe neutropenic phase until day 0, defined as severe neutropenic duration until day 0 (the first day of transplantation) of ≥5 days; MCFG, micafungin; VRC, voriconazole; ITC, itraconazole; LAMB, liposomal amphotericin B.